Age-related Macular Degeneration Market by Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), Treatment Type (Drugs, Laser Treatment), Distribution Channel - Global Forecast 2024-2030
The Age-related Macular Degeneration Market size was estimated at USD 11.17 billion in 2023 and expected to reach USD 11.92 billion in 2024, at a CAGR 7.18% to reach USD 18.16 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Age-related Macular Degeneration Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Age-related Macular Degeneration Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include Alcon Vision LLC, Alkahest, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., Bayer AG, Biogen Inc., Carl Zeiss AG, Clearside Biomedical, Inc., Coherus Biosciences, Inc., Graybug Vision, Inc., Gyroscope Therapeutics Limited by Novartis AG, Heidelberg Engineering GmbH, Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kodiak Sciences Inc., Merck & Co., Inc., Nicox SA, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..
Market Segmentation & Coverage
This research report categorizes the Age-related Macular Degeneration Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Dry Age-Related Macular Degeneration
Drugs
Hospital Pharmacies
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Age-related Macular Degeneration Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Age-related Macular Degeneration Market?
- What are the technology trends and regulatory frameworks in the Age-related Macular Degeneration Market?
- What is the market share of the leading vendors in the Age-related Macular Degeneration Market?
- Which modes and strategic moves are suitable for entering the Age-related Macular Degeneration Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Age-related Macular Degeneration Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing number of geriatric population across the world
- 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
- 5.1.1.3. Increasing diagnostics facilities for eye problems
- 5.1.2. Restraints
- 5.1.2.1. Current treatment limitations in age-related macular degeneration
- 5.1.3. Opportunities
- 5.1.3.1. Emerging research activities for reducing impact of age-related macular degeneration
- 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
- 5.1.4. Challenges
- 5.1.4.1. Limited skilled healthcare professionals
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Age-related Macular Degeneration Market, by Type
- 6.1. Introduction
- 6.2. Dry Age-Related Macular Degeneration
- 6.3. Wet Age-Related Macular Degeneration
- 7. Age-related Macular Degeneration Market, by Treatment Type
- 7.1. Introduction
- 7.2. Drugs
- 7.3. Laser Treatment
- 8. Age-related Macular Degeneration Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Hospital Pharmacies
- 8.3. Online Pharmacies
- 8.4. Retail Pharmacies
- 9. Americas Age-related Macular Degeneration Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Age-related Macular Degeneration Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Age-related Macular Degeneration Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Alcon Vision LLC
- 13.1.2. Alkahest, Inc.
- 13.1.3. Alkeus Pharmaceuticals, Inc.
- 13.1.4. Allegro Ophthalmics, LLC
- 13.1.5. Amgen Inc.
- 13.1.6. Annexon, Inc.
- 13.1.7. Apellis Pharmaceuticals, Inc.
- 13.1.8. Bayer AG
- 13.1.9. Biogen Inc.
- 13.1.10. Carl Zeiss AG
- 13.1.11. Clearside Biomedical, Inc.
- 13.1.12. Coherus Biosciences, Inc.
- 13.1.13. Graybug Vision, Inc.
- 13.1.14. Gyroscope Therapeutics Limited by Novartis AG
- 13.1.15. Heidelberg Engineering GmbH
- 13.1.16. Ionis Pharmaceuticals, Inc.
- 13.1.17. Janssen Pharmaceuticals, Inc.
- 13.1.18. Kodiak Sciences Inc.
- 13.1.19. Merck & Co., Inc.
- 13.1.20. Nicox SA
- 13.1.21. Regeneron Pharmaceuticals Inc.
- 13.1.22. Santen Pharmaceutical Co., Ltd.
- 13.1.23. Sun Pharmaceutical Industries, Inc.
- 13.1.24. Teva Pharmaceutical Industries Ltd.
- 13.1.25. Viatris Inc.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
- FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
- FIGURE 3. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
- FIGURE 7. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
- FIGURE 10. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 12. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook